CCKBR and neoplasm: Finally, because proglumide is a broad antagonist of both CCK1 and CCK2 receptors and is nonspecifically delivered throughout the animal, we employed the stable genetic downregulation of CCK2R in PDAC tumor cells to specifically address the cell-intrinsic role of this receptor isoform in the development of tumor fibrosis.